

Maelor Announces Launch of ContiSol® in Canada, and Appointment of Exclusive Volplex® Distributor in Greece and the Balkans

19 July 2005: Maelor plc ("Maelor" or the "Company"), the specialist healthcare products company, today announces the launch of ContiSol in Canada and a new distribution agreement for Volplex in southeast Europe.

ContiSol

Following the appointment of American Australian Medical, Inc. (AAM) as the exclusive ContiSol distributor for North America in April 2005, Maelor is pleased to report that the product has now been launched in Canada.

AAM is a marketer and distributor of specialist urological and pain management products throughout North America, making them the ideal distribution partner for ContiSol. Currently the company has 21 dedicated representatives and an experienced marketing team supporting the sales force.

ContiSol is a range of cleansing solutions designed to prolong the life of indwelling urethral catheters and to prevent blockages. By incorporating a bellows design it gently flushes the catheter, thus reducing the need for expensive and uncomfortable replacement. The nurse or patient administering ContiSol is able to control accurately both the rate and volume of delivery whilst maintaining the highest possible aseptic standards. ContiSol is also available in Spain, Greece and Cyprus, and is distributed in the UK and Ireland by Bard Limited under their brand name OptiFlo®. The product currently has a 46% share of the UK market, which is estimated to be worth in excess of £5 million (source: IMS).

Volplex

Maelor has signed an exclusive distribution agreement with V.I. Pharma International, SA (VIP) for the sale and marketing of Volplex, Maelor's blood plasma volume replacement product, in Greece, Cyprus, Albania, Bulgaria, Croatia, and Romania.

VIP is a company which operates in southeast Europe, and sells a range of innovative therapeutic and diagnostic products in the haematology and diabetes fields. The regulatory dossier has already been submitted by VIP in Greece, where the company aims to claim a significant share of the growing market, currently estimated to be around £350,000 annually.

Volplex (succinylated gelatin) is given as an intravenous infusion to substitute for blood volume lost by patients suffering from the effects of trauma, surgery or certain medical conditions which result in hypovolaemia (lower than normal blood volume). Since launch in 2003, the product has established itself by winning major contracts in the £8 million UK market through its distributor Cambridge Laboratories. Volplex has expanded its international franchise, gaining regulatory approval in Argentina where it will be launched later this year. In preparation for launch Maelor has established partners in Australia, Bangladesh, China, South Africa and South Korea.

Stephen Appelbee, CEO of Maelor, said:

"ContiSol is already approved for use in Canada, and AAM can give us immediate access both to the Canadian market and to local regulatory expertise in the world's biggest medical products market, the United States. They are also well placed to liaise with the University of Alberta, which is currently conducting a major clinical trial featuring ContiSol.

We are also pleased to welcome VIP as our Volplex distributor in Greece and the Balkans. This is a major step in the development of our first pharmaceutical product, Volplex, as Greece is our first regulatory submission in the European Union, outside the UK.”

For further information:

Maelor plc

Stephen Appelbee, Chief Executive Officer

01978 810153

Financial Dynamics

Ben Atwell/Lucy Briggs

0207 831 3113

Notes to Editors:

Maelor plc

Maelor is an AIM-listed specialist healthcare products company, which operates on a virtual basis, outsourcing both product development and manufacturing. The company has several products on the market including OptiFlo, ContiSol and Volplex.

Maelor has various products under development including micelle propofol, a reformulation of the world's biggest selling general anaesthetic.